BRAF and neoplasm: Our data suggest immune-stimulating effects of dabrafenib therapy may be at least partially due to altered MDSC function, a prediction supported by the reduction of PMN-MDSCs in BRAF-mut tumor-bearing mice after dabrafenib treatment.